Response Genetics, Inc. Announces Year-End 2007 Financials and Strategic Update Conference Call

Response Genetics, Inc. (NASDAQ: RGDX) will announce year-end 2007
financial results in a press release at 4 p.m. ET on Wednesday, March
26 and will follow with an annual strategic update during a conference
call scheduled for 5 p.m. ET on Wednesday, March 26.

To access the teleconference, please follow these instructions.

Teleconference Information:

Toll Free: 1-877-407-8033

International: 1-201-689-8033

Conference ID: 279501

A webcast of this event is available at
http://www.investorcalendar.com/IC/CEPage.asp?ID=127528

A replay of this teleconference is available until 4/5/2008. To
access the replay, follow these instructions:

Toll Free: 1-877-660-6853

International: 1-201-612-7415

Passcodes: Account #: 286 and Conference ID #: 279501

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI", the "Company") (NASDAQ: RGDX) is
engaged in the research and development of pharmacogenomic cancer
diagnostic tests based on its proprietary and patented technologies.
RGI´s technologies enable extraction and analysis of genetic
information from genes derived from tumor samples stored as
formalin-fixed and paraffin embedded specimens. RGI currently
generates revenue primarily from the sales of its proprietary
analytical pharmacogenomic testing services of clinical trial
specimens to the pharmaceutical industry. The Company was founded in
1999 and its principal headquarters are located in Los Angeles,
California. For more information, please visit
www.responsegenetics.com.

Forward Looking Statement Notice

Except for the historical information contained herein, this press
release and the statements of representatives of Response Genetics,
Inc. (the "Company") related thereto contain or may contain, among
other things, certain forward-looking statements, within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation,
statements with respect to the Company´s plans, objectives,
projections, expectations and intentions, such as the ability of the
Company to analyze cancer samples, the potential for using the results
of this research to develop diagnostic tests for cancer, the
usefulness of genetic information to tailor treatment to patients, the
ability of the Company to make its ResponseDx:Lung(TM) and
ResponseDX:Colon(TM) tests, including its ERCC-1 molecular diagnostic
test available in the first quarter of 2008, or at all, and other
statements identified by words such as "projects", "may", "could",
"would", "should", "believes", "expects", "anticipates", "estimates",
"intends", "plans" or similar expressions.

These statements are based upon the current beliefs and
expectations of the Company´s management and are subject to
significant risks and uncertainties, including those detailed in the
Company´s filings with the Securities and Exchange Commission. Actual
results, including, without limitation, actual sales results, if any,
or the application of funds, may differ from those set forth in the
forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company´s control). The
Company undertakes no obligation to publicly update forward-looking
statements, whether because of new information, future events or
otherwise, except as required by law.